Neurocrine Clinical Site

Dallas, Texas 75390-8857

2 studies enrolling now · 12 studies all time

What they study most

Anhedonia, Cerebral Palsy, Congenital Adrenal Hyperplasia, Dyskinesia, Major Depressive Disorder, Schizophrenia, Tourette Syndrome

Studies at this site

• Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Recruiting now
• Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Recruiting now
• Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia — Running, not enrolling
• Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy — Completed
• Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia — Completed
• Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study) — Running, not enrolling
• Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD) — Completed
• Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD — Completed
• Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome — Stopped early
• Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome — Stopped early
• Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome — Completed
• Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome — Completed